LB contains several components of interest for research into potential therapeutic targets . Two main components have been studied, circulating tumor cells (CTCs) and plasma . At present, most of the approaches in routine practice use plasma, in particular for activating and resistance mutations detection in EGFR in patients with advanced stage lung cancer.